GlassScriptPhysician profile
Scott D Ispirescu
NPI 1023148525
$10,454.00
in general payments reported to CMS, 2019-2025
31 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $1,022 · 2021: $1,473 · 2022: $1,572 · 2023: $2,043 · 2024: $1,183 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,918 · Education: $27.27 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.70 |
| Education | $27.27 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,722.36 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $814.25 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $797.84 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $720.81 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $715.73 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $577.94 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $575.85 | 2021-2025 | Caplyta |
| Allergan, INC. | $471.26 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $401.32 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $371.22 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $367.86 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $331.88 | 2019-2025 | Rexulti, Brintellix |
| Supernus Pharmaceuticals, INC. | $326.23 | 2022-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $248.99 | 2019 | |
| Adlon Therapeutics L.P. | $241.09 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $237.74 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $221.91 | 2019-2024 | Spravato |
| Alkermes, INC. | $209.00 | 2021-2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $208.06 | 2022-2024 | Quviviq |
| Corium, LLC | $184.06 | 2021-2023 | Azstarys |
| Tris Pharma INC | $151.03 | 2022-2025 | Dyanavel Xr |
| Eisai INC. | $125.66 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $124.96 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $73.58 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $65.82 | 2021-2023 | Secuado, Xelstrym |
| Almatica Pharma LLC | $55.54 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $34.80 | 2025 | Adzenys Xr-Odt |
| Biogen, INC. | $24.45 | 2024 | Zurzuvae |
| Alfasigma USA, INC. | $22.59 | 2021 | |
| Assertio Therapeutics, INC. | $16.35 | 2019 | |
| Harmony Biosciences LLC | $13.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ispirescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.